Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080522 |
| Name | anaplastic thyroid carcinoma |
| Definition | A thyroid gland carcinoma that is composed of undifferentiated cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma anaplastic thyroid carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF V600E | Dabrafenib + Trametinib | anaplastic thyroid carcinoma | sensitive | detail... |
| BRAF V600E | Vemurafenib | anaplastic thyroid carcinoma | predicted - sensitive | detail... |
| RET fusion | Selpercatinib | anaplastic thyroid carcinoma | sensitive | detail... |
| RET fusion | Pralsetinib | anaplastic thyroid carcinoma | sensitive | detail... |
| BRAF V600E PIK3CA M1043I | Dasatinib + Trametinib | anaplastic thyroid carcinoma | sensitive | detail... |
| BRAF V600E PIK3CA H1047R | Dasatinib + Trametinib | anaplastic thyroid carcinoma | sensitive | detail... |
| BRAF V600E PIK3CA N1044S | Dasatinib + Trametinib | anaplastic thyroid carcinoma | resistant | detail... |
| BRAF V600E PIK3CA E542K | Dasatinib + Trametinib | anaplastic thyroid carcinoma | resistant | detail... |
| BRAF V600E PIK3CA E542K | GSK2334470 + Trametinib | anaplastic thyroid carcinoma | sensitive | detail... |
| BRAF V600E PIK3CA N1044S | GSK2334470 + Trametinib | anaplastic thyroid carcinoma | sensitive | detail... |
| BRAF V600E PIK3CA N1044S | Dasatinib + MK2206 + Trametinib | anaplastic thyroid carcinoma | resistant | detail... |
| BRAF V600E PIK3CA E542K | Dasatinib + MK2206 + Trametinib | anaplastic thyroid carcinoma | resistant | detail... |
| BRAF V600E | Binimetinib + Encorafenib | anaplastic thyroid carcinoma | sensitive | detail... |
| BRAF V600E | Ravoxertinib | anaplastic thyroid carcinoma | sensitive | detail... |
| NRAS Q61K | Ravoxertinib | anaplastic thyroid carcinoma | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03181100 | Phase II | Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
| NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
| NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Terminated | ESP | 0 |
| NCT04238624 | Phase II | Cemiplimab + Dabrafenib + Trametinib | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04400474 | Phase II | Atezolizumab + Cabozantinib | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) | Completed | ESP | 0 |
| NCT04420754 | Phase I | AIC100 | Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04552769 | Phase II | Abemaciclib | Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | Completed | USA | 0 |
| NCT04675710 | Phase II | Dabrafenib + Pembrolizumab + Trametinib | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04759911 | Phase II | Selpercatinib | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT05059470 | Phase II | Pembrolizumab | IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC | Terminated | USA | 0 |
| NCT05119296 | Phase II | Pembrolizumab | Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | Recruiting | USA | 0 |
| NCT05453799 | Phase II | XmAb20717 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT05668585 | Phase Ib/II | Cetuximab + CFT1946 CFT1946 + Trametinib CFT1946 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | Completed | USA | GBR | FRA | ESP | DEU | 0 |
| NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
| NCT06079333 | Phase II | Dabrafenib + Trametinib | NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT) | Recruiting | NLD | 0 |
| NCT06235216 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab govitEcan in THYroid Cancers (SETHY) | Recruiting | ESP | 0 |
| NCT06639191 | Phase I | 177Lu-AKIR001 | [177Lu]Lu-AKIR001 First-in-human Study (AKIR001) | Not yet recruiting | SWE | 0 |
| NCT06790706 | Phase II | AB154 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (IMMUNORARE5) | Recruiting | FRA | 0 |
| NCT06902376 | Phase I | Cemiplimab + XL092 | XL092 and Cemiplimab in BRAF WT Thyroid Cancer (NEO-COMBATXL) | Recruiting | USA | 0 |